Priorix is a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain) and Wistar RA 27/3 rubella strains of viruses.
Priorix is indicated to protect against measles, mumps, and rubella. It works by helping the body to make its own antibodies which protect your child against these diseases.
Priorix is administered as a subcutaneous or Intramuscular injection in the deltoid region or in the anterolateral area of the thigh.
A single 0.5 mL dose of the reconstituted vaccine is recommended.
The Canadian Immunization Guide recommends immunization at 12 months of age, or as soon as practicable thereafter.
A second dose of MMR is recommended at least 1 month after the first dose, for the purpose of better measles protection.
Priorix is currently licensed outside the USA in over 100 countries, and it is recommended for use in individuals aged ≥9 months, according to a 1- or 2-dose schedule depending on the country.
Clinical Trial NCT01702428: Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
This study will evaluate the consistency of the immune response to three different lots of GSK Biologicals' trivalent investigational MMR vaccine (NV_MMR) and compare its immunogenicity to the US standard of care comparator vaccine M-M-R II, Merck and Co., Inc. (COM_MMR) in children during their second year of life.
The INV_MMR vaccine will be given as one of three consistency lots manufactured to target potencies designated as INV_MMR_L1, INV_MMR_L2 and INV_MMR_L3.
The COM_MMR vaccine will be given as one of two lots designated COM_MMR_L1 and COM_MMR_L2 and will be analysed as pooled lots within the study.
The MMR vaccine will be co-administered with Varivax (VV), Havrix (HAV) and (in the US sub-cohort only) Prevnar 13 (PCV-13) which are routinely administered to children of this age in the US.